Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 3/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11812636 | 0.83 | ADORA2A (0.46) | TDP1ALDH1A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL6691054 | 0.80 | KDM4E (0.46) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL10698333 | 0.74 | KDM4E (0.52) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL17604141 | 0.73 | ALDH1A1 (0.37) | TDP1TP53ALDH1A1LMNACYP1A2 | |
| SCHEMBL863014 | 0.71 | GRK6 (0.44) | KDM4ETP53MAPTALDH1A1LMNA | |
| SCHEMBL24389364 | 0.70 | ALDH1A1 (0.58) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL6673478 | 0.70 | KDM4E (0.61) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL30361621 | 0.70 | AHCY (0.52) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL24113793 | 0.69 | ALDH1A1 (0.56) | TDP1KDM4ETP53MAPTALDH1A1 | |
| SCHEMBL12198516 | 0.69 | ALDH1A1 (0.56) | TDP1KDM4ETP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | TDP1 48/4885KDM4E 2495/4885TP53 4326/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | TDP1 201/4885KDM4E 1745/4885TP53 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.